Using the cost-effectiveness of allogeneic islet transplantation to inform iPSC derived beta cell therapy reimbursement

In the present study a cost-effectiveness analysis of Allogeneic Islet Transplantation was performed and the financial feasibility of a Human Induced Pluripotent Stem Cell (hiPSC) derived Beta Cell therapy was explored. Previously published cost and health benefit data for Islet Transplantation was utilised to perform the cost-effectiveness and sensitivity analyses. It was determined that, over a 9 year time horizon, Islet Transplantation would become cost saving and ‘dominate’ the comparator. Over a 20 year time horizon, Islet Transplantation would incur significant cost savings over the comparator (£59,000). Finally, assuming a similar cost of goods to Islet Transplantation and a lack of requirement for immunosuppression, a hiPSC-derived Beta Cell therapy would dominate the comparator over an 8 year time horizon.